Clinical Trials Logo

Filter by:
NCT ID: NCT06068972 Completed - Clinical trials for Non-Healing Ulcer of Skin

Retrospective Database Review at LTC and SNFs

Start date: April 20, 2022
Phase:
Study type: Observational

The goal of this observational study is to compare the differences in wound outcomes when the MolecuLight imaging procedure is used in combination with standard of care wound assessment in long term care and skilled nursing facilities. The main outcome studied is healing of ulcers after 12-weeks, along with other outcomes such as occurrence of infection, complications, and antimicrobial use. Medical records from the past were reviewed, where patients receiving the MolecuLight procedure were compared to those who did not.

NCT ID: NCT06068946 Active, not recruiting - Weight Loss Clinical Trials

VK2735 for Weight Management Phase 2

VENTURE
Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once weekly.

NCT ID: NCT06068933 Recruiting - Clinical trials for Mild Cognitive Impairment

K-HEARS MCI: Hearing Health Care for Korean American Older Adults With Mild Cognitive Impairment

K-HEARS MCI
Start date: December 12, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to develop and assess the feasibility, acceptability, and preliminary efficacy of a community-delivered, affordable, and accessible hearing care intervention tailored to the needs of community-dwelling Korean American (KA) older adults with mild cognitive impairment (MCI) and their care partners that integrates a low-cost over-the-counter amplification device and hearing rehabilitation through a randomized controlled pilot study. Each dyad will consist of the study participant and their care partner.

NCT ID: NCT06068894 Recruiting - Intestinal Health Clinical Trials

Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults

Start date: June 13, 2024
Phase: N/A
Study type: Interventional

This study aims to establish the safety of a 15 g/day dose of pure prebiotics ß(1-4) galacto-oligosaccharides (GOS) and GOS enriched with N-Acetyl-D-lactosamine, a building block of gut glycoproteins and human milk oligosaccharides (LAcNac, humanized GOS, hGOS) in healthy adult individuals. The safety and tolerability of the dose and the biological signature of GOS and hGOS in healthy adults will be established through a pilot clinical trial to assess GOS and hGOS effects vs placebo on (i) gastrointestinal adverse effects as measured by the Gastrointestinal Symptom and Severity Checklist (GSSC), (ii) increased abundance of beneficial gut bacteria and restoration of the gut microbiome saccharolytic potential, (iii) modulation of biomarkers of inflammation and (iv) evaluation of intestinal barrier function.

NCT ID: NCT06068868 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Start date: November 13, 2023
Phase: Phase 1
Study type: Interventional

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in escalating doses until the maximum tolerated dose (MTD) is determined. Approximately 60 adult participants with a diagnosis of AML will be enrolled worldwide. Participants will receive intravenous (IV) infusions of ABBV-787 during the approximately 3 year duration a participant is followed. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

NCT ID: NCT06068790 Active, not recruiting - Clinical trials for Urinary Incontinence

Incontinence Analysis After HoLEP Using 28Fr Versus 22Fr Sheath

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

The rationale for this study is to assess whether there is a difference in HoLEP outcomes in smaller 22Fr instruments compared to our standard 28Fr sheaths.

NCT ID: NCT06068764 Recruiting - Clinical trials for Coronary Artery Disease

Etomidate Versus Propofol in CABG Surgery

ETOPRO
Start date: December 5, 2023
Phase: Phase 4
Study type: Interventional

The objective of this single-blinded randomized controlled interventional clinical trial is to learn about the efficacy and long-term safety of etomidate compared to propofol as an anesthesia induction agent in patients undergoing coronary artery bypass graft (CABG) surgery. The primary aim of this study is to determine whether patients receiving etomidate or propofol exhibit similar requirements for vasopressor or ionotropic agents during both the intraoperative and postoperative periods. To achieve this goal, participants who are scheduled for CABG surgery will be randomly assigned to receive either etomidate or propofol as the principal hypnotic agent. The researchers will then compare the effects of these two anesthesia induction agents on various factors, including the need for hemodynamic support, hemodynamic stability, duration of mechanical ventilation, length of stay in the intensive care unit (ICU), and overall hospital length of stay. Additionally, they will assess whether there are disparities in mortality rates and readmission rates within a 6-month timeframe after the surgery. By comparing the outcomes between the two groups, the study aims to provide valuable insights into the potential differences in vasopressor or ionotropic agent requirements between etomidate and propofol. This information can help inform clinical decision-making and potentially optimize anesthesia management strategies for patients undergoing CABG surgery.

NCT ID: NCT06068712 Completed - Healthy Clinical Trials

Proactive and Reactive Attention to Negative Templates

Start date: October 11, 2014
Phase: N/A
Study type: Interventional

EEG Measures during Visual Search Task. In this line of research, the researchers having participants receive a positive (target) template cue, negative (distractor) template cue, or neutral (non-informative) template cue. Note: This is a re-analysis of previously collected data.

NCT ID: NCT06068699 Completed - Adherence, Patient Clinical Trials

Postcards to Improve Remote Monitoring Adherence Among Veterans

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

We tested the effect of informational postcards on improving remote monitoring adherence among Veterans with pacemakers and implantable cardioverter-defibrillators in a stepped-wedge randomized controlled trial.

NCT ID: NCT06068634 Enrolling by invitation - Infertility Clinical Trials

Patient-Centered Care Survey

PCCS
Start date: October 16, 2023
Phase:
Study type: Observational

The key to patient-centered care is to identify what the patient perceives as meaningful. The primary objective of this research is to evaluate which aspects of patient-centered care are priorities to infertility patients, and if those priorities vary by geographical region.